Research Paper Title:

PT-AML: Machine learning framework to identified personalized treatments for acute myeloid leukemia

Journal: TBD

Authors: Raghvendra Mall^{1#}, Siddhi Jani², ...

Keywords: []

SC: Deep Learning; Machine Learning; AML; Drug Sensitivity; Precision Medicine; Mutations; Cell

State; Mechanism of Action

Abstract: [Checklist: Statements are factually accurate; provides a concise summary that is interesting and attracts attention; provides key background, purpose of article, and key findings from the study]

ABSTRACT EXAMPLE:

First line: State the topic; should be related to the title

Resistance to cell death is a leading hallmark of cancer. Therapies aimed at activating cell death are therefore of high interest to improve treatment and understanding the induction of cell death during cancers is a key strategy to identify therapies.

Second and third sentences: Expand on the critical background information relating to the topic, including why it is a relevant

Fourth sentence and beyond: These sentences should mirror the subsections from your results outline

Last sentence: These results demonstrate...

SC:

Research Article Outline:

PT-AML: Machine learning framework to identified personalize treatments for acute myeloid leukemia

[Checklist: Statements are factually accurate, key references from Kanneganti lab and Others ref lists are included]

1. Introduction [Checklist: limit to 3 paragraphs; describe the key concepts; provide relevant background information in the context of our lab's interests; attract the readers attention and inform about the purpose of the article and what you aim to achieve]

J	<i>•</i> .
2.	
3.	
4.	
5.	
6.	Discussion

ec.

Figures

[Checklist: concise title and legend; include labels and enough detail to be understood without the text; fonts and colors follow lab template, and the formatting is correct; no image duplications]

Figure Checklist

First authors and coauthors are responsible for ensuring that: 1) data are reproducible and there are no image duplications; 2) data have been independently verified by 2 people other than the first author (provide their names here).

See the example figure on the next page for clarifications. Please carefully check each item and sign off on the completion of this checklist before bringing figures to Thiru or Rebecca. Finalized figures must be approved by Thiru before you begin writing the manuscript.

Many of these points also apply for review figures. Particularly, for review figure color scheme ideas, refer to the colors used in this poster from InvivoGen: https://www.invivogen.com/sites/default/files/invivogen/resources/documents/2016-poster_tlr-nlr-invivogen_0.pdf

I confirm that my figures meet the above criteria, along with any other journal-specific criteria.

Date

¹ Figure # is at the bottom right of each figure in Arial font, size 14, bold (ex: **Figure 1**)

² Figure title is at the top of the page in Arial font, size 11, bold (ex: **Figure title**)

³ Figure panels are denoted by bold, uppercase letters in Arial font, size 14 (ex: **A**)

⁴ All text within the figure panels is in Arial font, size 11, not bold (ex: Media)

⁵ Western blot images include labels for the lanes along the top of the image; other labels are also at the top

⁶ Lane and border thickness are set to 1 pt with dotted lines on western blots set to 0.5 pt

⁷ No shadows or shadow lines are present

⁸ Terminology and labeling are used consistently throughout all figures (ex: Casp11^{-/-})

⁹ Colors should be consistent throughout all figures (wild type, black; knock-out, red)

¹⁰ Red and green are not included on the same graph (due to red-green colorblindness)

¹¹ All microscopy images include the scale bar, which is defined in the figure legend

¹² Arrows can be used in microscopy images to callout cell death or other noteworthy staining; these arrows should be triangles (ex:)


¹³ All blots and gels have molecular weights (or base pair size for DNA/RNA) for all proteins or DNA/RNA species indicated

¹⁴ All blots must have an accompanying raw blot file (see example in Figure 2)

¹⁵ **There are no image duplications** (no duplicated blots, microscopy images, etc.) and data are reproducible and have been validated by 2 additional people as listed above

PT-AML: Machine learning framework to identified personalized treatments for acute myeloid leukemia

Graphical Abstract











Figure 1





















Supplementary Figure 3



						0.555					
		30.224 +/-	44.050	40.342	CO 00F	+/-	0.004	0.744 +/-	0.50	0.742 +/-	0.550
Ridge Regressor	LS + Cell Line	1.972	44.859	+/- 2.906	60.005	0.052	0.281	0.034	0.53	0.032	0.556
	MFP + Cell	29.925 +/-		40.103		0.559 +/-		0.747 +/-		0.745 +/-	
Ridge Regressor			43.476	+/- 2.891	57.257	0.052	0.336	0.034	0.579		0.578
Tadgo Tagroocor						0.556					
		30.125 +/-		40.249		+/-		0.745 +/-		0.743 +/-	
Linear SVR	LS + Cell Line	1.955	44.968	+/- 2.898	60.366	0.051	0.278	0.034	0.527	0.032	0.557
						0.559					
		29.934 +/-	40.004	40.088	F7 704	+/-	0.000	0.747 +/-	0.570	0.745 +/-	0.574
Linear SVR	Line	1.922	43.894	+/- 2.894	57.731	0.052	0.328	0.034	0.572	0.033	0.571
		21.824 +/-		29.865		0.787 +/-		0.887 +/-		0.886 +/-	
RF	LS + Cell Line		39.626		52.077	0.021	0.442	0.012	0.665		0.656
						0.817					
	MFP + Cell	20.749 +/-		28.287		+/-		0.904 +/-			
RF	Line	1.221	40.156	+/- 1.834	52.528	0.021	0.437	0.012	0.661	0.9 +/- 0.01	0.649
						0.728					
Y05		24.288 +/-	20.042	31.939	E2 220	+/-	0.422	0.853 +/-	0.657	0.835 +/-	0.65
XGBoost	LS + Cell Line	1.212	39.843	+/- 1.755	52.339	0.038	0.432	0.022	0.657	0.022	0.65
	MED . Call	22.937 +/-		30.101		0.782 +/-		0.884 +/-		0.867 +/-	
XGBoost		1.009	40.534		52.876	0.037	0.43	0.004 17	0.655		0.642
жовоос						0.786		-			
		21.529 +/-		28.748		+/-		0.887 +/-		0.872 +/-	
LightGBM	LS + Cell Line	1.119	39.497	+/- 1.63	52.091	0.029	0.441	0.016	0.664	0.016	0.655
		00.000		04.40=		0.752		0.00= /		0.0=4	
11.1.004	MFP + Cell	23.232 +/-	40.071	31.123 +/- 1.651	52.554	+/- 0.037	0.432	0.867 +/- 0.021	0.657	0.854 +/- 0.021	0.644
LightGBM	Line	1.079	40.071	- /- 1.031	52.554	0.037	0.432	0.021	0.057	0.021	0.044
		26.35 +/-		37.256		0.623 +/-		0.789 +/-		0.789 +/-	
Cathoost	LS + Cell Line		39.24	+/- 2.51	52.449	0.044	0.436	0.028	0.66		0.655
23.0000						0.725					
	MFP + Cell			31.919		+/-		0.851 +/-		0.85 +/-	
Catboost	Line	1.48	39.044	+/- 2.432	52.032	0.036	0.439	0.021	0.663	0.017	0.652
						0.718					
D1 11 1	10.0-11.1	23.511 +/-	45.151	32.091 +/- 2.1	58.69	+/- 0.032	0.32	0.847 +/- 0.019	0.565	0.836 +/- 0.018	0.552
DNN	LS + Cell Line	1.431	45.151	+/- ∠. ۱	50.09	0.032	0.32	0.019	0.565	0.016	0.332

25.422

37.113 +/-

37.031 +/-

36.871 +/-

0.644

0.489

0.611

56.177

54.904

55.6

55.14

42.647 +/- 1.582

CV

(r)

(r2)

0.555

0.824

0.018

0.643 +/-

0.646 +/-

0.645 +/-

0.0076 0.389

0.0067

0.0069

+/-

0.356

0.393

0.397

0.908 +/-

0.802 +/-

0.803 +/-

0.803 +/-

0.0047

0.0043

0.0042

0.01

0.596

0.627

0.63

0.624

0.899 +/-

0.800 +/-

0.800 +/-

0.799 +/-

0.0057

0.0041

0.0056

0.01

0.617

0.627

0.618

0.587

Test

Test Pearson Pearson Spearman Spearman

(r)

CV

(r)

Test

(r)

Table 1: Performance comparison of different machine learning models

1.05

40.697

40.85

40.70

MFP + Cell 18.189 +/-

SMILES + 26.312 +/-

SMILES + 26.026 +/-

SMILES + 26.267 +/-

Cell Line 0.370

Cell Line 0.228

Cell Line 0.420

Line

DNN

Graph Attention Netw ork + FFNN

CNN + FFNN

LSTM + FFNN

Features

Methods

Used CV (MAE)

Test

(MAE)

CV

Test

(RMSE) (RMSE) CV (r2)

MFP + Mutations + AUC	22.004 +/- 1.185	39.604	32.911 +/- 1.944	52.854	0.709 +/- 0.038	0.429	0.842 +/- 0.022	0.655	0.843 +/- 0.018	0.64
MFP + AUC + Pathw ays + Modules	25.35 +/- 1.324	39.398	36.136 +/- 2.137	52.482	0.646 +/- 0.044	0.432	0.803 +/- 0.027	0.657	0.804 +/- 0.023	0.647
MFP + AUC + Pathw ays + Mutations	25.59 +/- 1.377	39.507	36.397 +/- 2.138	52.792	0.641 +/- 0.044	0.431	0.8 +/- 0.027	0.657	0.801 +/- 0023	0.648
MFP + AUC + Pathw ays + Onco +Var	24.765 +/- 1.473	39.718	35.574 +/- 2.351	52.744	0.658 +/- 0.042	0.427	0.81 +/- 0.026	0.654	0.81 +/- 0.021	0.643
MFP+ AUC+ Modules+ Mutations	25.858 +/- 1.415	38.94	36.688 +/- 2.168	52.229	0.635 +/- 0.045	0.441	0.796 +/- 0.028	0.664	0.797 +/- 0.023	0.656
MFP + AUC + Modules + Onco + Var	24.768 +/- 1.405	39.517	35.575 +/- 2.239	52.653	0.657 +/- 0.042	0.432	0.81 +/- 0.026	0.657	0.809 +/- 0.021	0.648
MFP + AUC + Mutations + Onco + Var	24.749 +/- 1.477	39.289	35.578 +/- 2.396	52.387	0.657 +/- 0.044	0.437	0.81 +/- 0.027	0.661	0.81 +/- 0.022	0.651
MFP + AUC + Mutations + Modules + Onco + Var	24.743 +/- 1.51	39.177	35.559 +/- 2.445	52.323	0.657 +/- 0.043	0.44	0.81 +/- 0.026	0.664	0.81 +/- 0.021	0.655
MFP + AUC + Mutations + Pathw ays + Onco + Var	25.675 +/- 1.556	39.803	36.518 +/- 2.458	53.268	0.638 +/- 0.045	0.419	0.798 +/- 0.028	0.647	0.797 +/- 0.023	0.638
MFP + AUC + Modules + Pathw ays + Onco + Var	24.718 +/- 1.461	39.422	35.531 +/- 2.354	52.581	0.658 +/- 0.046	0.433	0.811 +/- 0.028	0.658	0.81 +/- 0.023	0.648
MFP + AUC + Mutations + Modules + Pathw ays	27.653 +/- 1.425	39.403	38.459 +/- 2.177	52.601	0.599 +/- 0.48	0.436	0.774 +/- 0.03	0.66	0.775 +/- 0.026	0.652

Supplementary Table 1: Ablation study of different feature sets used for the optimal model construction.

Test

40.465

39.542

40.149

39.337

CV (MAE)

20.862 +/- 1.39

AUC 19.556 +/- 1.005

AUC 20.996 +/- 1.183

MFP + AUC 27.458 +/- 1.207

Features Used

MFP + Onco +Var

MFP + Pathways +

MFP + Modules +

MFP + Mutations +

+ AUC

(MAE) CV (RMSE)

38.85 +/-

31.731 +/-

30.409 +/-

31.81 +/-

32.911 +/-

1.856

2.305

1.866

2.001

Test

0.591 +/-

0.728 +/-

0.751 +/-

0.728 +/-

0.709 +/-

0.054

0.037

0.03

0.033

0.406

0.43

0.412

0.429

(RMSE)

54.114

52.46

53.287

52.509

CV

0.774 +/-

0.852 +/-

0.867 +/-

0.854 +/-

0.843 +/-

0.028

0.017

0.014

0.015

Test

0.626

0.642

0.628

0.644

CV

0.768 +/-

0.853 +/-

0.866 +/-

0.853 +/-

0.842 +/-

0.035

0.022

0.017

0.019

Test

0.637

0.656

0.642

0.655

CV (r2) Test (r2) (Pearson r) (Pearson r) (Spearman r) (Spearman r)

Background:

- 1. 699 cell lines from CCLE with 19,177 gene expression profiles. This information was downloaded from Cancer Dependency Map Public 21Q3. We filtered the original data consisting of 1,377 cell lines → 699 cell lines to keep only those cell lines with COSMIC ids to match the drug-response dataset from GDSC portal. We include 10 features related to cell line metadata including age, gender, type, name of cell line etc. for the cancer cell lines.
- 2. Genes of interest include genes which are part of several inflammasome/inflammatory cell death pathways including:
- a) Reactome inflammasome, b) KEGG nod like signaling pathway, c) GO biological process inflammasome complex, d) Reactome pyroptosis, e) Necroptotic signaling pathway from GO, f) PANoptosis pathway, g) Immunogenic cell death pathway (ICR) → total of 170 (167 of which are present in the 19,177 genes)
- 3. Seven pathways considered for inflammatory cell death as mentioned above.
- 4. We got the mutation profile and copy number variation profile for the 170 genes of interest. The mutation profile and copy number variation was obtained from Harmonizome database from Mayan lab.
- 5. We removed genes which had no variation in expression, mutation or CNV across cell lines including: Mutation_ERBIN, Mutation_NLRP2B, Mutation_STMP1, Mutation_PYDC2, Mutation_CARD18, CNV ERBIN, CNV NLRP2B, CNV STMP1
- 6. Total Features include:
- a) Cell Line Features (10); b) Pathways (7); c) Expression (167); d) Mutation (162); e) CNV (164)
- 7. The dose response information is obtained from GDSC portal. It contains drug response for a particular cell line with prediction variables: IC50score and Z-score. In the GDSC portal, the Z-score is used to determine sensitive and resistant drugs with cut-offs of -2 and 2 respectively. We use the —log10(IC50score) as our y variable (term to predict). It contains 398 unique drugs and 989 cell lines.
- 8. The viability information is also obtained from GDSC portal. It contains cell viability at different dosage levels. **Currently not used.**

Methods:


- 1. The gene expression profile for each cell line is quantile normalized (19,177 genes), scaled and converted to z-scores.
- 2. T-sne plots are made for 699 cell lines with cancer types based on expression profiles as well as the features we have engineered.
- 3. A complexheatmap visualization of the different features used and how they look across the 699 cancer cell lines.

Background:

- We obtained drug information for 399 drugs from GDSC portal and the cell line information for 699 cell lines from CCLE.
- 2. We curated and added each drug's target from resources like Drug Bank, its SMILES, Inchikey, Molecular weight, molecular formula representations from PubChem, CheMBL and NCBI API.
- 3. There are a total of 373 unique drugs available from this dataset.
- 4. We find a total of 379,005 drug-cell line sensitivity profiles from GDSC portal (GDSC 1 & 2 combined).
- 5. After filtering, removing duplicates and combined drug plus cell line features, we end up with a total of 151,636 drug-cell line combination profiles consisting of 253 drugs and 693 cell lines.

Method:

- 1. We perform inner joins with drug profiles and cell line profiles to get drug-cell features used for the predictive models.
- 2. For each drug, we have its known targets. We perform a random walk with restart to get a random walk score for each drug using 'diffusr' package in R. It provides the probability of a drug impacting all the genes in our cell line's expression profile. This affinity is based on topology and doesn't consider individual gene's expression in a particular cell line. To get a cell line specific affinity, we multiply the random walk scores with corresponding genes' expression levels. Using this information and the gene set for each pathway, we estimate the distance of a drug from each of the 7 inflammasome related pathways using 'AUCell' package in R.
- 3. For each drug, we can estimate its molecular fingerprint representation using the RDKIT package in python.
- 4. For each drug, we can also estimate its representation using a transfer-learning based approach. We pass the drug SMILES to a TF-LSTM autoencoder trained on over 2 million drug SMILES and obtain a embedding vector representation of the drug which can be fed to a machine learning algorithm.
- 5. All the cell line information (expression, mutation, copy number) + drug information (vector representation) + pathway enrichments (pathway activation based on expression) and distance of a pathway from a drug's known targets are used as features to predict the drug response.
- 6. We used a variety of machine learning methods including:
 - 1. Linear Regression
 - 2. Elastic Net
 - 3. SVM
 - 4. Random Forests
 - 5. Xgboost
 - 6. LightGBM
 - 7. Feed Forward Neural Networks (DNN)
 - 8. Graph Attention Network (GAT) + DNN
 - 9. Convolutional Neural Network (CNN) + DNN
 - 10. Long-Short Term Memory (LSTM) + DNN
- 7. We built different models on training set (565 cell lines) and test on a complete independent test set (128 cell lines on which no training is performed)
- 8. We highlight the variable importance (i.e. the top features) driving the prediction for each of these different machine learning models and performance is highlighted in Table.



Research Article Checklist should be placed after presentation

Research Article Checklist

Name

accura consis and in	ate; 2) tently a formatio	and coauthors are responsible for ensuring that: 1) all statements are factually references to seminal publications and Kanneganti lab publications are used not wherever appropriate (refer to the reference lists); 3) the correct mouse source on is provided.							
		nformative, concise, and includes keywords							
	Autho	r List: all authors are included; names are spelled correctly							
	Keywo	ords: searchability; citability							
	Abstra	act: Overall summary (provides key background, purpose, and findings)							
	0	Statements are factually accurate							
	0	Concise							
	0	Followed example							
	Outlin	e or Full Article:							
	0	Introduction: 3 paragraphs; key concepts and background							
	0	Statements are factually accurate							
	References (Key refs from Kanneganti lab and Others ref lists)								
	 Discussion: 3 paragraphs; concise summary of info presented; contextualized; 								
		highlights any clinical relevance							
	0	Followed examples							
	Figure	es:							
	0	Concise title and legend							
	0	Labels and enough detail to be understood without text							
	0	Followed lab template (correct formatting, no shadows, no typos)							
	0	No image duplications							
		I have checked for the above points during my review and provided the necessary ne first author.							

Date